近日，康德（深圳）生物技术股份有限公司正式通过ISO13485：2016医疗器械质量管理体系国际认证， 标志着康德生物在癌症检测体外诊断试剂研发、生产及服务全流程的质量管理能力达到国际标准，可持 续地为全球客户提供卓越可靠的产品与服务。 世界卫生组织提出，全球大约1/3的癌症完全可以预防，1/3的癌症可以通过早期发现得到根治，1/3的癌 症可以运用医疗措施延长生命、减轻痛苦。由此可见，癌症早筛早诊的重要性不言而喻。事实上，临床 上大部分患者确认患癌时多处于中晚期，错过了最佳治疗时间，而有效可靠的早期癌症检测体外诊断试 剂技术，正恰好能解决临床上部分癌症早期难发现的痛点。 康德（深圳）生物技术股份有限公司致力于研发生产高品质的癌症早筛早检体外诊断试剂产品，此次通 过ISO13485体系国际认证是康德（深圳）生物技术股份有限公司构建全面质量管理体系的重要里程碑。 不仅标志着公司质量管理水平迈上新台阶，更是对康德生物在研发、生产、销售等各个环节严格遵循国 际标准、确保产品安全与有效性的有力证明。同时，也见证了公司将高质量技术及产品赋能癌症精准诊 疗领域，为人类健康事业砥砺前行的使命和初心。 康德生物成功通过ISO1 ...

Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [5][9]. Core Insights - The company is a leading manufacturer of disposable gloves, particularly nitrile gloves, and has significantly expanded its production capacity from 19 billion units in 2019 to 56 billion units by mid-2025, establishing itself as a global leader in the nitrile glove market [1][15]. - The nitrile glove industry is experiencing robust demand due to its superior performance and low allergy rates, with global rubber glove demand projected to reach approximately 325 to 375 billion units by 2025, maintaining a strong growth trend [1][40]. - The company has built a strong cost advantage through technological leadership, self-supply of raw materials, and economies of scale, making it difficult for competitors to replicate its cost structure [2][47]. Company Overview - The company generates over 90% of its revenue from medical protective products, primarily nitrile and PVC gloves, with a significant portion of its sales coming from overseas markets, particularly North America and Europe [20][31]. - The management team is stable, with key executives having extensive experience in manufacturing, supply chain management, and international sales [27][30]. Industry Analysis - The nitrile glove market is characterized by a high-quality price ratio, with increasing penetration in various applications beyond medical use, driven by heightened public health awareness [31][36]. - The supply structure is dominated by manufacturers from Malaysia and China, with the demand primarily concentrated in the U.S. and Europe, which account for about 60% of global consumption [44][45]. Financial Projections - The company is expected to achieve revenues of 10.01 billion, 12.56 billion, and 14.48 billion yuan for the years 2025, 2026, and 2027, respectively, with year-on-year growth rates of 5.15%, 25.41%, and 15.34% [11][9]. - The net profit forecast for the same period is projected to be 1.26 billion, 1.71 billion, and 2.19 billion yuan, reflecting growth rates of -14.1%, 36.2%, and 27.9% [11][9].

时代天使在德国的代理律师事务所Arnold Ruess代理律师Dr. Arno Riße表示："时代天使尊重并将遵守杜 塞尔多夫统一专利法院的裁定，但与此同时，我们将积极举证，证明暂停Live Now功能中特定模块的 判定是不合理的。时代天使高度重视知识产权，并始终谨慎确保不侵犯任何有效专利权。" 多年来，时代天使始终专注于隐形正畸领域创新解决方案的研发。公司拥有多项前沿的解决方案和产 品，包括：屡获奖项的angelButton天使扣、angelHook天使钩、A6前导下颌解决方案(已迎来十周年)、 angel KiD时代天使儿童解决方案以及IRS智能根骨系统。时代天使致力于为市场带来公平、健康的竞争 环境，让医生与患者共同受益。 智通财经APP获悉，时代天使科技有限公司(06699，下称"时代天使")表示，德国杜塞尔多夫统一专利法 院(Unified Patent Court of Düsseldorf)下达临时禁令，要求公司暂停使用自动更新方案功能("live now")中 的特定模块，这对使用时代天使隐形矫治产品的医生和患者影响甚微。该临时禁令仅适用于部分欧洲国 家，不包括西班牙、瑞士、英国及爱尔兰。公 ...

原标题：宁波深化建设全域高水平创新型城市 制造业"冠军之城"创新马力足 聚焦重大战略科研方向，宁波正推动主导优势产业向现代化产业集群转型，探索以优势链主型企业 为主体组建创新联合体。 在余姚，舜宇集团联合产业链上下游企业和科研院所打造光电信息产业创新联合体，协同攻克光电 信息多项关键核心技术，产业链产值节节攀高；在宁波石化经济技术开发区，900多公里管线"链"就一 条协同共生、高效循环的绿色石化产业链，"链主"镇海炼化牵头组建创新联合体，在攻克20多项核心技 术的同时，推动链上企业共享共用技术成果。 面对新一轮科技革命和产业变革，宁波通过政策牵引，引导企业精准切入新赛道，形成竞争新优 势。如人形机器人赛道，宁波在"科创甬江2035"重点研发计划设立人形机器人专项，支持高校院所建设 人形机器人交叉学科群，鼓励整机和关键零部件企业高水平建设企业科技创新载体……如今，宁波已拥 有整机人形机器人企业8家，核心零部件企业220家。去年，宁波人工智能核心产业营收增速达11.3%。 马年春节，各地洋溢着浓浓的年味，宁波不少企业就已吹响了复工"集结号"。在宁波达尔机械科技 有限公司车间，100多条数字化生产线高速运转，一款款 ...

证券之星消息，截至2026年2月13日收盘，美好医疗(301363)报收于34.88元，上涨6.57%，换手率 6.75%，成交量25.19万手，成交额8.6亿元。 2月13日的资金流向数据方面，主力资金净流入1.13亿元，占总成交额13.19%，游资资金净流入3679.75 万元，占总成交额4.28%，散户资金净流出1.5亿元，占总成交额17.47%。 美好医疗2025年三季报显示，前三季度公司主营收入11.94亿元，同比上升3.28%；归母净利润2.08亿 元，同比下降19.25%；扣非净利润2.03亿元，同比下降17.85%；其中2025年第三季度，公司单季度主营 收入4.62亿元，同比上升2.56%；单季度归母净利润9390.02万元，同比上升5.89%；单季度扣非净利润 9270.68万元，同比上升9.56%；负债率11.43%，投资收益490.31万元，财务费用-2739.1万元，毛利率 39.34%。美好医疗（301363）主营业务：医疗器械精密组件及产品的设计开发、制造和销售,为全球医 疗器械企业提供从产品研发到批量交付的全流程一站式服务。 该股最近90天内共有4家机构给出评级，买入评级4家； ...

北交所周报 交投活跃度节前回落，北交所优化再融资 2026 年 02 月 23 日 核心观点 分析师 范想想 ：010-8092-7663 ：fanxiangxiang_yj@chinastock.com.cn 分析师登记编码：S0130518090002 张智浩 ：zhangzhihao_yj@chinastock.com.cn 分析师登记编码：S0130524100001 相关研究 1. 【银河北交所】2026 年度策略_"小而美"到"强 而久"，推动北证高质量发展 2. 【银河北交所】"十五五"：北交所引领中小企业 再进阶 3. 【银河北交所】2025 年度中期策略_并购协同促 新格局，提质扩容迎新供给 www.chinastock.com.cn 证券研究报告 请务必阅读正文最后的中国银河证券股份有限公司免责声明 1 相对沪深 300 表现图 2026-02-23 资料来源：iFinD，中国银河证券研究院 ⚫ 北证 50 指数周涨幅为+0.58%。2 月 9 日至 2 月 13 日，北证 50 涨幅为 +0.58%。北交所 294 家上市公司中，共 103 家公司周涨幅为正，其中新股 爱得科技（+144 ...

Group 1 - The core investment theme post-Spring Festival revolves around "price increases" and "revaluation of physical assets," particularly in resource, chemical, and midstream manufacturing sectors, leveraging China's pricing power amid global uncertainties [1][2] - The technology sector, particularly driven by AI, remains a key focus, with sub-sectors like computing power, applications, and robotics expected to remain active due to industrial catalysts [1][2] - The recovery of export chains, non-bank financials, and certain consumer and real estate chains are seen as important supplements to market trends under the backdrop of internal and external demand recovery [1] Group 2 - CITIC Securities emphasizes that price increases are a core configuration clue for Q1, with a focus on sectors like chemicals, non-ferrous metals, power equipment, and new energy, while also increasing exposure to undervalued insurance and brokerage stocks [2] - Historical data indicates that February and the period around the Spring Festival are strong for market movements, with small-cap stocks showing a 100% probability of rising from the Spring Festival to the Two Sessions [3] - Guojin Securities highlights the importance of balancing global physical assets against Chinese assets, recommending commodities like copper, aluminum, and oil, as well as sectors with global comparative advantages like equipment exports and domestic manufacturing [4] Group 3 - Industrial sectors experiencing structural price increases due to supply-demand gaps are primarily in midstream materials and manufacturing, with a focus on chemicals, steel, and high-end manufacturing [5] - The potential for recovery in the export chain is noted, particularly in industries with significant exposure to the U.S. market that will benefit from reduced tariffs [5] - The policy uncertainty surrounding tariffs and trade is expected to favor gold as a risk hedge, with market participants anticipating potential shifts in U.S. trade policy [6] Group 4 - Attention is drawn to the post-holiday inventory replenishment in commodities, with a continued positive outlook on technology applications, particularly in semiconductors and AI [7] - Quantum technology is highlighted as a sector receiving dual catalysts from policy and technological advancements, with significant developments in quantum key distribution networks [8] - The AI industry revolution is identified as a key investment theme, focusing on computing power, storage, and applications, with a strong emphasis on the performance of high-growth sectors [9] Group 5 - Localized opportunities are expected in AI applications linked to overseas trends and robotics associated with the Spring Festival, with a cautious approach to market movements anticipated [10] - The current bull market logic remains intact, with a recommendation for investors to maintain confidence despite short-term volatility, focusing on sectors with high securities ratios [11]

Financial Data and Key Metrics Changes - The company achieved record annual worldwide revenue of nearly $201 million, marking over 20% growth year-over-year [5][21] - Fourth quarter worldwide revenue grew 15% to a record $56.3 million, with U.S. revenue at $53.5 million, representing 13.9% growth [20] - Positive Adjusted EBITDA of $5.1 million in the fourth quarter, a 176.2% improvement over the prior year, with a 9.1% Adjusted EBITDA margin [23][24] - Net loss narrowed to $1.6 million or $0.04 per diluted share in the fourth quarter, compared to a net loss of $4.5 million or $0.11 per diluted share last year [22] Business Line Data and Key Metrics Changes - The company reported a 22% increase in U.S. physicians using its technologies, with nearly 22,000 procedures performed in 2025 [6][20] - INTRA Ti was launched recently, expected to enhance procedural efficiency in SI joint fusion [9][10] - iFuse Bedrock Granite has been one of the fastest-growing platforms, significantly outpacing the overall deformity market growth rate [11] Market Data and Key Metrics Changes - International revenue in the fourth quarter was $2.9 million, growing 38.8%, driven by the reception of iFuse TORQ [20] - The company secured favorable reimbursement positions, including NTAP for iFuse TORQ TNT and TPT for iFuse Bedrock Granite, enhancing access and adoption [6][11] Company Strategy and Development Direction - The company aims to lead the market for patients with compromised bone, focusing on innovation and market development [8] - A strategic partnership with Smith+Nephew was announced to expand reach in the trauma market, allowing trauma surgeons access to breakthrough technologies [16][29] - The next five years are viewed as an innovation super cycle, with plans to launch unique technologies targeting new clinical adjacencies [7][55] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in long-term growth potential, supported by a robust pipeline of innovative products and expanding market opportunities [28] - The company expects worldwide revenue of $228.5 million to $232.5 million in 2026, implying year-over-year growth of 14%-16% [25][26] - Management highlighted the importance of allowing tailwinds to materialize before fully incorporating them into revenue expectations [52][83] Other Important Information - The company exited 2025 with $147.8 million in cash and equivalents, marking a significant improvement in cash consumption compared to the previous year [24] - The company plans to add 10 new territories in 2026 to capture market opportunities [16][66] Q&A Session Summary Question: On the Smith+Nephew partnership, how did it come about and its potential contribution? - Management expressed excitement about the partnership, highlighting its potential to expand access to trauma solutions and allow the sales force to focus on market development [29][30] Question: Regarding clinical data showing similar outcomes for IPM physicians, will this increase engagement? - Management noted the growing interest in interventional business and the launch of INTRA Ti, which aligns with interventional spine physicians' workflows [32][34] Question: Can you clarify the guidance for Adjusted EBITDA in 2026? - Management indicated that while they expect an increase in Adjusted EBITDA, it would be slightly below $20 million [44] Question: What is the expected impact of INTRA Ti on the ASC market? - Management highlighted that INTRA Ti is designed for the ASC market and is expected to drive additional sales due to its simplicity and reimbursement coverage [46][62] Question: Can you discuss the cadence of revenue and the expected tailwinds? - Management noted that they expect more tailwinds than ever before, with a strong physician base and improved reimbursement backdrop [52][53]

SI-BONE (NasdaqGM:SIBN) Q4 2025 Earnings call February 23, 2026 04:30 PM ET Company ParticipantsAnshul Maheshwari - CFO and COOCaitlin Roberts - Director of MedTech Equity ResearchDavid Saxon - Managing DirectorLaura Francis - CEOMathew Blackman - Managing DirectorPatrick Wood - Managing DirectorSaqib Iqbal - VP of FP&A and Investor RelationsTravis Steed - Managing DirectorConference Call ParticipantsNone - AnalystNone - AnalystOperatorGood afternoon, and welcome to SI-BONE's Fourth Quarter 2025 Earnings Co ...

Financial Data and Key Metrics Changes - The company generated record annual worldwide revenue of nearly $201 million, marking over 20% growth year-over-year [5][20] - Fourth quarter worldwide revenue grew 15% to a record $56.3 million, with U.S. revenue at $53.5 million, representing 13.9% growth [19][20] - The company achieved its first full year of positive Adjusted EBITDA, with a margin of 9% in the fourth quarter [6][23] - Net loss narrowed to $1.6 million or $0.04 per diluted share in the fourth quarter, compared to a net loss of $4.5 million or $0.11 per diluted share last year [22][23] - The company exited 2025 with $147.8 million in cash and equivalents, an increase of $2.1 million from the third quarter [24] Business Line Data and Key Metrics Changes - The U.S. physician base grew by 22%, with over 2,400 physicians performing nearly 22,000 procedures in 2025 [5][20] - The company launched the INTRA Ti product, which is expected to enhance procedural efficiency in ambulatory surgery centers [9][10] - iFuse Bedrock Granite has been one of the fastest-growing platforms, significantly outpacing the overall deformity market growth rate [11] Market Data and Key Metrics Changes - International revenue in the fourth quarter was $2.9 million, growing 38.8%, driven by the reception of iFuse TORQ [19][20] - The company secured favorable reimbursement positions, including NTAP for iFuse TORQ TNT and TPT for iFuse Bedrock Granite, enhancing access and adoption [5][11] Company Strategy and Development Direction - The company aims to lead the sacroiliac joint fusion market and expand into new clinical adjacencies, targeting unmet needs for patients with compromised bone [6][8] - The partnership with Smith+Nephew is expected to enhance market penetration in trauma solutions [16][30] - The company anticipates an innovation super cycle over the next five years, with regular product launches targeting new clinical adjacencies [7][57] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term growth potential of the business, supported by a robust pipeline of innovative products and expanding market opportunities [27] - The company expects worldwide revenue of $228.5 million to $232.5 million in 2026, implying year-over-year growth of 14%-16% [25][26] - Management highlighted the importance of allowing tailwinds to materialize before fully incorporating them into revenue expectations [54][86] Other Important Information - The company achieved positive free cash flow in the fourth quarter, generating nearly $500,000, ahead of its previously stated goal [24] - The company plans to add 10 new territories in 2026 to capture market opportunities [16][69] Q&A Session Summary Question: How did the Smith+Nephew partnership come about and its potential contribution? - Management expressed excitement about the partnership, highlighting its potential to expand access to trauma solutions and allow the sales force to focus on spine and interventional markets [30][32] Question: Will the INTRA Ti product create more engagement among interventional physicians? - Management confirmed that the INTRA Ti product is designed to improve procedural efficiency and is expected to drive growth in the interventional business [34][49] Question: What is the rationale behind the high teens growth guidance for 2026? - Management explained that the guidance considers the impact of new products and reimbursement coverage, with a focus on prudent expectations early in the year [86] Question: What is the expected ramp-up for the Smith+Nephew partnership in 2026? - Management indicated that activity is expected to start in March, with a ramp-up in Q2 and Q3 in preparation for Q4 [74][75]